ESCMID weekly news 12.04.2022

12 April 2022: ESCMID Weekly
Having trouble viewing this email? View in your browser.

 

Weekly News
12 April 2022

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

 

ECCMID 2022 now available in the ESCMID app

The ECCMID 2022 event is now available in the ESCMID app. Inside you can find the most up to date programme, venue information, ECCMID extras and other important ECCMID information at your fingertips.
 

Search ‘ESCMID’ in your mobile app store!

 

 

ECCMID Keynote Fireplace

The deadline to register for the ECCMID 2022 Keynote Fireplace sessions is approaching soon! Register now to join with a small group to meet Keynote lecturers and explore in detail the topics covered in their presentations. See which Keynotes are hosting sessions and register by Friday 15 April.

IMMEM XIII – Abstract submission closing soon!

Only two days left to submit your abstract for the 13th International Meeting on Microbial Epidemiological Markers (IMMEM XIII). Abstracts will be accepted in multiple categories, and you can find the categories and abstract guidelines on the conference website.

Submission closes 14 April, 2022!

Ecraid Work Package meeting, ECCMID 2022

Ecraid aims to establish a self-sustaining clinical research network in Europe to advance clinical research on infectious diseases. This session will describe past performance and current activities and is an open meeting for anyone. Spaces are limited so register now!

The ESCMID Antimicrobial Stewardship Certificate – Registration open!

Registration is now open for the brand-new ESCMID Antimicrobial Stewardship Certificate 2-year training programme. As spaces are limited, check the programme and register now.

ESCMID Online courses available for registration

ESCMID has several online education courses that are available for registration now! Review them all and register for the ones that pique your interest such as ‘COVID-19 and Liver disease’ and ‘Personalised phage therapy: basic principles of monitoring and treatment’ both taking place in June!

Inhaled ciclesonide for outpatient treatment of COVID-19

This trial assesses the efficacy of inhaled ciclesonide in reducing adverse outcomes in COVID-19 outpatients. The authors’ findings are consistent with the EMA’s taskforce statement that there is currently insufficient evidence for the benefit of inhaled corticosteroids for COVID-19 patients.

 

 

 

 

Nahoru